ATRA Atara Biotherapeutics Inc.

31.08
-0.78  -2%
Previous Close 31.86
Open 31.65
Price To Book 4.23
Market Cap 1434704300
Shares 46,161,657
Volume 100,243
Short Ratio
Av. Daily Volume 409,712

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initial data due 1H 2019.
ATA188
Multiple sclerosis
Phase 3 data due 1H 2019.
ATA 129 (tab-cel) - ALLELE
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
Phase 3 data due 1H 2019.
ATA 129 (tab-cel) - MATCH
Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT)
Phase 1/2 trial to be initiated 2H 2018.
ATA129 and KEYTRUDA
Nasopharyngeal carcinoma (NPC)
Phase 2 endpoint not met December 2015
PINTA 745
Protein-energy wasting
Phase 2 presentation at ASH December 2018.
ATA 129
Epstein-Barr virus (EBV-PTLD)
Phase 1 presentation at AACR noted best ORR for a subset of 11 malignant pleural mesothelioma patients who also received pembrolizumab and lymphodepleting chemotherapy was 72%.
Autologous T Cells
Malignant pleural disease

Latest News

  1. Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019
  2. Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
  3. The Atara Biotherapeutics (NASDAQ:ATRA) Share Price Has Gained 122%, So Why Not Pay It Some Attention?
  4. Atara Biotherapeutics to Participate in Upcoming Conferences
  5. How attacking a virus in cancer patients helped a Peninsula company target MS
  6. Atara Biotherapeutics Announces Presentations Highlighting Next-Generation CAR T Platform and Mesothelin-Targeted CAR T Clinical Results at American Association of Cancer Research (AACR) Annual Meeting 2019
  7. Atara Biotherapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress
  8. Consolidated Research: 2019 Summary Expectations for T-Mobile US, WestRock, Shake Shack, Atara Biotherapeutics, CorVel, and Transdigm Group — Fundamental Analysis, Key Performance Indications
  9. At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
  10. Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference
  11. Company News For Jan 4, 2019
  12. Why Delta Air Lines, Atara Biotherapeutics, and Skyworks Solutions Slumped Today
  13. Atara Biotherapeutics Announces Planned Chief Executive Officer Transition
  14. Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors
  15. Should You Avoid Atara Biotherapeutics Inc (ATRA)?
  16. Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS)
  17. Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
  18. Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
  19. Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018
  20. Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy